Abstract:Retinal gene therapy is leading the neurological gene therapy field, with 32 ongoing clinical trials of recombinant adeno-associated virus (rAAV)-based therapies. Importantly, over 50% of those trials are using restricted promoters from human genes. Promoters that restrict expression have demonstrated increased efficacy and can limit the therapeutic to the target cells thereby reducing unwanted off-target effects. Retinal ganglion cells are a critical target in ocular gene therapy; they are involved in common diseases such as glaucoma, rare diseases such as Leber's hereditary optic neuropathy, and in revolutionary optogenetic treatments. Here, we used computational biology and mined the human genome for the best genes from which to develop a novel minimal promoter element(s) designed for expression in restricted cell types (MiniPromoter) to improve the safety and efficacy of retinal ganglion cell gene therapy. Gene selection included the use of the first available droplet-based single-cell RNA sequencing (Drop-seq) dataset, and promoter design was bioinformatically driven and informed by a wide range of genomics datasets. We tested seven promoter designs from four genes in rAAV for specificity and quantified expression strength in retinal ganglion cells in mouse, and then the single best in nonhuman primate retina. Thus, we developed a new human-DNA MiniPromoter, Ple345 (NEFL), which in combination with intravitreal delivery in rAAV9 showed specific and robust expression in the retinal ganglion cells of the nonhuman-primate rhesus macaque retina. In mouse, we also developed MiniPromoters expressing in retinal ganglion cells, the hippocampus of the brain, a pan neuronal pattern in the brain, and peripheral nerves. As single-cell transcriptomics such as Drop-seq become available for other cell types, many new opportunities for additional novel restricted MiniPromoters will present.

A Novel Adenoviral Vector Which Mediates Hypoxia-Inducible Gene Expression Selectively in Neurons

Retroviral Vector-Mediated Hypoxia-Regulated Neurotrophin-3 Gene Transfer Reduces Apoptosis Induced by Hypoxia in PC12 Cells

Development of Efficient AAV2/DJ-Based Viral Vectors to Selectively Downregulate the Expression of Neuronal or Astrocytic Target Proteins in the Rat Central Nervous System

Development of a hypoxia-responsive vector for tumor-specific gene therapy

Construction and identification of the recombinant retroviral vector to carry out hypoxia-regulated expression of neurotrophin-3

Efficient Therapeutic Gene Expression in Cultured Rat Hippocampal Neurons Mediated by Human Foamy Virus Vectors: A Potential for the Treatment of Neurological Diseases

New MiniPromoter Ple345 (NEFL) Drives Strong and Specific Expression in Retinal Ganglion Cells of Mouse and Primate Retina

A New Finding Concerning Adenoviral-Mediated Gene Transfer: A High-Level, Cell-Specific Transgene Expression in the Neural Stem Cells of Adult Mice

Adeno-associated Viral Vector-Mediated Hypoxia-Regulated VEGF Gene Transfer Promotes Angiogenesis Following Focal Cerebral Ischemia in Mice

Deletion of the Virion Host Shut-off Gene Enhances Neuronal-Selective Transgene Expression from an HSV Vector Lacking Functional IE Genes

Hypoxia-Regulated Neurotrophin-3 Expression by Multicopy Hypoxia Response Elements Reduces Apoptosis in Pc12 Cells

Cis-regulatory elements driving motor neuron-restricted viral payload expression within the mammalian spinal cord

Development of adenoviral vectors that transduce Purkinje cells and other cerebellar cell-types in the cerebellum of a humanized mouse model

Exploitation of Hypoxia Regulatory Vectors for Gene Therapy of Renal Anemia

Gene Transfer into the Nervous System using Recombinant Herpes Virus Vectors

Retrovirus Mediated Hypoxia-Responsive Element-Regulated Neurotrophin-3 Transduction Attenuates Brain Injury Following Focal Cerebral Ischemia in Rats

Construction and functional identification of siRNA adenoviral vector targeting HIF-1α in mouse

Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promoters

bFGF expression mediated by a hypoxia-regulated adenoviral vector protects PC12 cell death induced by serum deprivation.

Adenovirus-mediated brain-derived neurotrophic factor expression regulated by hypoxia response element protects brain from injury of transient middle cerebral artery occlusion in mice.

Viral vectors with cluster of differentiation gene promoters to target specific cell types in the brain